Allergy Asthma Immunol Res.
2020 Mar;12(2):371-374. 10.4168/aair.2020.12.2.371.
Non-episodic Angioedema With Eosinophilia Successfully Treated With Reslizumab
- Affiliations
-
- 1Department of Pulmonary, Allergy and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. rkduddle@hanmail.net
- 2Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
- 3Allergy and Clinical Immunology Research Center, Hallym University College of Medicine, Chuncheon, Korea.
- KMID: 2468469
- DOI: http://doi.org/10.4168/aair.2020.12.2.371
Abstract
- No abstract available.
MeSH Terms
Figure
-
Figure Change of angioedema and eosinophil inflammation markers before and after treatment with reslizumab. (A) Angioedema was observed on both upper and lower extremities accompanied by a body weight increase of 4 kg. (B) Angioedema disappeared after treatment with reslizumab. (C) Elevated eosinophil count dramatically decreased after treatment with reslizumab. White arrows show the admission for intravenous corticosteroid injection and black arrows show reslizumab administration. (D)The levels of IL-5, EDN and ECP were decreased after treatment of reslizumab. IL, interleukin; EDN, eosinophil-derived neurotoxin; ECP, eosinophil cationic protein.
Reference
-
1. Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, O'Connell EJ, Kohler PF. Episodic angioedema associated with eosinophilia. N Engl J Med. 1984; 310:1621–1626.
Article2. Cho HJ, Yoo HS, Kim MA, Shin YS, Ye YM, Nahm DH, et al. Clinical characteristics of angioedema with eosinophilia. Allergy Asthma Immunol Res. 2014; 6:362–365.
Article3. Nakachi S, Inokuma S. Eleven cases of angioedema with eosinophilia treated in a single hospital in Japan. Allergol Int. 2012; 61:259–263.
Article4. Scranton SE, Wild CA, England RW. Episodic angioedema with eosinophilia: successful treatment with imatinib. Ann Allergy Asthma Immunol. 2008; 100:172–174.
Article5. Matucci A, Liotta F, Vivarelli E, Dies L, Annunziato F, Piccinni MP, et al. efficacy and safety of mepolizumab (anti-Interleukin-5) treatment in Gleich's syndrome. Front Immunol. 2018; 9:1198.
Article6. McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019; 199:433–445.
Article7. Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract. 2015; 3:167–174.
Article
